Sterling Capital Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1,584.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,920 shares of the biopharmaceutical company’s stock after purchasing an additional 88,344 shares during the quarter. Sterling Capital Management LLC’s holdings in Gilead Sciences were worth $13,999,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new position in Gilead Sciences in the second quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the 2nd quarter worth $25,000. PFS Partners LLC raised its position in Gilead Sciences by 101.1% during the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 96 shares in the last quarter. Wiser Advisor Group LLC bought a new stake in Gilead Sciences during the 2nd quarter valued at $30,000. Finally, Wilkerson Advisory Group LLC lifted its holdings in shares of Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
- Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
- Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
- Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
- Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
- Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement
Insiders Place Their Bets
In related news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.
Wall Street Analyst Weigh In
GILD has been the subject of several recent research reports. Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Truist Financial increased their target price on shares of Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Morgan Stanley cut their target price on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $159.81.
Get Our Latest Analysis on GILD
Gilead Sciences Stock Down 0.7%
Shares of GILD traded down $1.15 during trading hours on Friday, hitting $156.04. The company had a trading volume of 6,070,692 shares, compared to its average volume of 5,700,578. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $193.48 billion, a PE ratio of -58.44 and a beta of 0.31. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51. The company’s fifty day moving average price is $149.10 and its two-hundred day moving average price is $137.85.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter last year, the company earned $2.01 earnings per share. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
Gilead Sciences Profile
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
